Bharat Biotech seeks DCGI's nod to conduct Covaccine booster test in 2-18 age group
Bharat Biotech is the first company to apply for permission from DCGI for testing booster dose in the age group of 2-18 years. Currently the vaccine is under vaccination for two doses for the 15-18 age group and the vigilance dose for the age group above 18 years.
Hyderabad-based pharma company Bharat Biotech has sought permission from the Drug Controller General of India (DCGI) to test covaccine as a COVID vaccine booster dose in the age group of 2-18 years. Sources gave this information. The company has applied for permission a week ago. It has already conducted trials in the age group 2-18 for two doses of Covaccine.
Bharat Biotech has also received Emergency Use Authority (EUA) approval for two doses for children aged 6-12 years. Bharat Biotech has also applied for 2-5 year old Emergency Use Authorization (EUA), but the Subject Expert Committee (SEC) has sought more data.
Bharat Biotech is the first company in India to apply for permission from DCGI for testing booster doses in the age group of 2-18 years. Currently, Covaccine is available under the National COVID Immunization Program for two doses for the age group 15-18 and for the age group above 18 years for the vigilance dose.
People are scared of Corona's new variant XE. Experts have suggested to be cautious about the new variant XE. Children are most likely to be affected by the XE variant. In Chandigarh, Dr Suman Singh told that if the children are to be kept safe, then their vaccination has to be ensured 100 percent. In this direction, special vaccination camps are being organized in the city for the vaccination of children.